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Abstract
This manuscript reviews the primary and secondary endpoints of pivotal phase III trials with immunomodulatory drugs in
multiple sclerosis (MS). Considering the limitations of previous trial designs, we propose new standards for the planning of
clinical trials, taking into account latest insights into MS pathophysiology and patient-relevant aspects. Using a systematic
overview of published phase III (pivotal) trials performed as part of application for drug market approval, we evaluate the
following characteristics: trial duration, number of trial participants, comparators, and endpoints (primary, secondary, magnetic
resonance imaging outcome, and patient-reported outcomes). From a patient perspective, the primary and secondary endpoints of
clinical trials are only partially relevant. High-quality trial data pertaining to efficacy and safety that stretch beyond the time frame
of pivotal trials are almost non-existent. Understanding of long-term benefits and risks of disease-modifying MS therapy is
largely lacking. Concrete proposals for the trial designs of relapsing (remitting) multiple sclerosis/clinically isolated syndrome,
primary progressive multiple sclerosis, and secondary progressive multiple sclerosis (e.g., study duration, mechanism of action,
and choice of endpoints) are presented based on the results of the systematic overview. Given the increasing number of available
immunotherapies, the therapeutic strategy in MS has shifted from a mere “relapse-prevention” approach to a personalized
provision of medical care as to the choice of the appropriate drugs and their sequential application over the course of the disease.
This personalized provision takes patient preferences as well as disease-related factors into consideration such as objective
clinical and radiographic findings but also very burdensome symptoms such as fatigue, depression, and cognitive impairment.
Future trial designs inMSwill have to assign higher relevance to these patient-reported outcomes and will also have to implement
surrogate measures that can serve as predictive markers for individual treatment response to new and investigational immuno-
therapies. This is an indispensable prerequisite to maximize the benefit of individual patients when participating in clinical trials.
Moreover, such appropriate trial designs and suitable enrolment criteria that correspond to the mode of action of the study drug
will facilitate targeted prevention of adverse events, thus mitigating risks for individual study participants.
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Background
Since the development of the first immunotherapy interferon
beta-1b in 1995 (see Table 1), a number of immunomodu-
latory substances have been authorized for the disease-
modifying treatment of multiple sclerosis (MS), namely by
reducing relapse rates [13, 25, 58]. The mechanisms of ac-
tion have been fully elucidated for only few of these drugs.
While a positive effect on the autoreactive, inflammatory
immune response is considered proven, direct neuroprotec-
tive effects are unlikely.
All drugs licensed to date were tested in 1- to 2-year
(rarely longer) pivotal trials, mostly against placebo [20],
although more recently, active comparators have also be-
gun to be applied. From the patient’s point of view, some
of the primary and secondary endpoints of these studies
have limited relevance [27, 65]. Moreover, methodologi-
cally sound data on these drugs’ efficacy and safety (or
detrimental effects), beyond the duration of these trials, are
practically non-existent. The little data covering 3 years or
more of application mostly derive from “extension studies”
to initial phase III studies or from registers such as
“MSBase” [36]. Specialized statistical analyses are applied
to compensate for the poor methodological quality of “ob-
servational studies” in order to gain insight into the effi-
cacy of immunomodulatory treatments (including com-
pared with each other). However, the “real-world” data
gathered in registers are generally not suited for such anal-
yses [31]. Overall, these factors suggest a general ap-
proach to designing clinical MS trials that leaves room
for improvement and which has hampered our understand-
ing of the long-term benefits and risks of disease-
modifying MS treatment. However, these deepened in-
sights are urgently needed to enable neurologists to pro-
ceed from a mere “relapse-preventative” strategy when
prescribing immunotherapies towards provision of person-
alized medical services that take the multiple facets of the
disease and patient preferences into consideration [22, 45]
and also adopts the aim of targeted prevention of adverse
events.
Investigative goal
The goal of this study is, firstly, to set out an overview
of the primary and secondary endpoints of pivotal phase
III trials in MS. Secondly, based on this summary, as
well as our analysis of the shortcomings of clinical trial
design to date, we propose a number of suggestions for
improvement. Here, we also draw on the latest insights
into MS pathophysiology, as well as aspects relevant for
patients, particularly the implementation of “patient-re-
ported outcome measures” (PROM). Moreover, we
describe the ongoing, significant demand for trials with
therapeutic agents that modify disease progression, for
which there have been too few controlled studies to
date.
Materials and methods
Our research of the available literature yielded a system-
atic overview of published pivotal phase III MS trials
performed to provide evidence for drug marketing ap-
proval (so-called pivotal trials). We took as a starting
point an assessment of 21 randomized, controlled phase
III trials on relapsing-remitting multiple sclerosis
(RRMS) presented in Torkildsen et al. [74]. As all of
the latter were completed prior to May 21, 2015, we
augmented them with our own research into the litera-
ture, focusing on further completed and published phase
III MS trials (inclusion criteria), as well as extending
analysis of all the included trials to the disease courses
relapsing multiple sclerosis (RMS), primary progressive
MS (PPMS), secondary progressive MS (SPMS), and
clinically isolated syndrome (CIS). Drugs not approved
for the market despite phase III trial were not included
(exclusion criteria). The literature was searched using
PubMed, as well as the European public assessment
reports (EPAR) of the European Medicines Agency
(EMA) and the dossier assessments of early benefit as-
sessments conducted by the German Institute for Quality
and Efficiency in Health Care (IQWiG). The PubMed
search was conducted using the keywords Multiple
Sclerosis, Phase 3, trial, with last access on 2-15-2019.
The following characteristics of the phase III trials were
analyzed: trial duration, sample size, comparator drugs (pri-
mary, secondary, MRI (magnetic resonance imaging) out-
comes, as well as patient-reported outcome measures
(PROM)).
Results
Table 1 of the Appendix summarizes the characteristics of the
29 assessed pivotal phase III trials. Below we describe the key
results of our investigation of the trials for the disease courses
RRMS, RMS, SPMS, PPMS, and CIS.
Trial duration
The analysis showed that the phase III RRMS trials con-
ducted since the 1990s had a duration of approximately 2
years, with some few exceptions (e.g., EVIDENCE trial,
interferon beta-1a, 1-year duration). For RMS, the trial
duration was also generally 2 years. Exceptions here were
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the 1-year TRANSFORMS trial (fingolimod, approved
2011) and the TOWER trial (teriflunomide, approved
2013), which had a variable duration, but was already
completed 48 weeks after inclusion of the last patient.
Alone, the PRECISE trial (glatiramer acetate for CIS, ap-
proved 2001) had a study duration of 3 years. Only re-
cently have trials longer than 2 years been carried out,
including the DECIDE trial (daclizumab for RRMS, 144
weeks, approved 2016, market withdrawal 2018) and the
ORATORIO trial in PPMS (ocrelizumab, 120 weeks, ap-
proved 2018).
Number of participants in MS pivotal trials
In recent years, the number of trial participants has in-
creased significantly. While the first pivotal interferon
beta 1b trial MSSG only included 372 patients, the
DECIDE trial (daclizumab) recruited 1841 patients.
One of the reasons for this is that relapse rates have
decreased significantly over the last 20 years, for in-
stance because many patients are already being treated
with immunomodulatory agents and therefore patients
with milder disease course are more likely to be recruit-
ed for drug trials. Thus, today significantly higher case
numbers are needed to reach statistical significance
using annual relapse rate as primary endpoint, with ab-
solute differences between investigational medicinal
product (IMP) and comparator drug sometimes averag-
ing just < 0.2 relapses per year. Miniscule effects that
only reach statistical significance by inflation of sample
size suggests that such trial results are of questionable
clinical relevance. However, it should be noted that one
advantage of larger sample sizes is a greater chance of
detecting rare side effects.
Comparator drugs
The earliest RRMS trials tested the IMP against placebo as no
other immunomodulatory agents had yet been developed.
However, more recently, trials are increasingly carried out
against active comparators, such as against interferon beta-
1a in the RRMS trials CARE MS-1 (alemtuzumab),
DECIDE (daclizumab), and EVIDENCE (SC vs. IM interfer-
on beta-1a). Glatiramer acetate was used as comparator drug
in the BEYOND trial (interferon beta-1b). In RMS, seven
placebo-controlled trials and four trials (TRANSFORMS
(fingolimod), CARE MS-2 (alemtuzumab), TENERE
(teriflunomide), and OPERA I + II (ocrelizumab)) with inter-
feron beta-1a as active comparator were carried out. In the
RMS trial REGARD (interferon beta-1a) glatiramer acetate
served as active comparator. The cytotoxic agent
mitoxantrone for SPMS was tested against placebo in the
MIMS trial, as was the monoclonal antibody ocrelizumab
for PPMS in the ORATORIO trial. All four trials in CIS were
also placebo-controlled: CHAMPS (interferon-β1a),
BENEFIT (interferon-β1b), PRECISE (glatiramer acetate),
and REFLEX (interferon-β1a).
Endpoints
In RRMS trials, relapse rate was most frequently selected
as primary endpoint. Disability progression, measured ac-
cording to the “Expanded Disability Status Scale (EDSS)”
for the quantification of neurological disability and con-
firmed after 12 or 24 weeks, was selected as primary
endpoint in two trials (interferon-β1a, MSCRG, and
alemtuzumab, CARE MS 1), but served only as secondary
endpoint in most. Apart from adverse events, key second-
ary or explorative endpoints included MRI endpoints,
such as number and volume of gadolinium-enhancing le-
sions and T2-hyperintense or T1-hypointense lesions in
cranial MRI and, most recently, also the progression of
cerebral atrophy [61]. For the 12 RMS trials, only relapse
rate was selected as primary endpoint, albeit in the case of
alemtuzumab (CARE MS 1 trial) in combination with
disability progression. The pattern was similar for clini-
cally isolated syndrome (CIS): the primary endpoints of
the PRECISE trial (glatiramer acetate) were the rate of
conversion to clinically definite MS as defined by a sec-
ond clinical event, while the BENEFIT trial (interferon-β
1b) measured conversion to both clinically definite MS
and McDonald MS, as well as the annual relapse rate
and the degree of disability. Apart from the primary end-
point (“disability progression confirmed at 12 weeks”),
the PPMS trial on ocrelizumab (ORATORIO trial) also
investigated secondary endpoints such as “disability pro-
gression confirmed at 24 weeks”, MRI endpoints, as well
as a patient-reported outcome (quality of life according to
the SF-36 (Short Form (36) Health Survey)).
Patient-reported outcome measures (PROM)
In many cases, patients and physicians differ in the im-
portance ascribed to particular symptoms and conse-
quences of the disease [27, 65]. In general, patients tend
to focus far more on disability progression impacting
quality of life, rather than disease progression as mea-
sured by anatomical, biological, and clinical data. As
such, patients generally understand disease progression
as the worsening of symptoms, with fatigue, depression,
cognitive impairment, pain, spasticity, sleep disturbance,
loss of visual functioning, and mobility among those con-
sidered most burdensome [16, 17, 24, 27, 57, 60, 63, 65,
77, 78, 80]. Many of these symptoms can be easily quan-
tified using internationally established and validated pa-
tient questionnaires.
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Virtually, no drug approval trial has systematically in-
vestigated PROM. Where investigated, the focus is on fa-
tigue, which is considered by many MS patients to be one
of the most troubling symptoms [79]. Here, two examples
are the TENERE and TEMSO trials (both teriflunomide,
RMS), which investigated fatigue as secondary endpoint
using the “Fatigue Impact Scale (FIS)”. In the ocrelizumab
trials (OPERA I, OPERA II, ORATORIO), health-related
quality of life (HRQoL) was measured using the
established, generic survey SF-36, which comprises the
section vitality, physical functioning, bodily pain, general
health perceptions, physical role functioning, emotional
role functioning, social role functioning, and mental
health. Nevertheless, measuring HRQoL is far from stan-
dard in clinical MS trials, as evidenced by the CLARITY
trial for the oral drug cladribine [34], which did not include
any PROM parameters [21]. Overall, PROM are still in-
vestigated less frequently as primary or secondary end-
points than relapse rate, disease progression, or MRI
parameters.
Discussion
Deficits in the design of phase III trials to date
Systematic analysis of the phase III trials included in this
overview showed that the approval of new substances for
the treatment of multiple sclerosis were as a rule random-
ized, controlled studies of at least 1 year and each included
several hundred, sometimes over 1000, patients. This, in
principle, suggests that an established approach to design-
ing MS clinical trials exists to a greater extent than in other
neurological disorders. However, on closer inspection, it
becomes clear that our approach to MS clinical trial design
urgently needs to redirect focus towards patient needs, as
opposed to biological indicators and surrogate measures of
dubious clinical importance.
In the EMA’s “Guideline on clinical investigation of
medicinal products for the treatment of Multiple
Sclerosis” [30], relapse rate and disability progression are
singled out as the most important primary endpoints. The
guideline distinguishes between the “accumulation of dis-
ability” in terms of relapse rate in RMS and disability pro-
gression in SPMS or PPMS in phase III trials, with clini-
cally measured prevention or delay of disability progres-
sion recommended as primary endpoint for SPMS and
PPMS. For patients with RRMS or SPMS with relapsing
MS (RMS), both relapse rate and the time to relapse are
accepted as primary outcomes. Relapse rate, or that is, the
proportion of relapse-free patients along with the progres-
sion of disability should, in addition to MRI outcomes, be
investigated as secondary endpoints, insofar as they have
not already been examined as primary endpoints.
Furthermore, the EMA guideline calls for more emphasis
on PROM, as symptoms such as subjective visual function,
pain, bladder control, depression, sleep disorder, fatigue,
and cognitive dysfunction are enormously important for
quality of life and are considered more crucial by some
patients than purely somatic outcomes [26, 65].
Analysis of the phase III trials to date highlights sig-
nificant deficits in pivotal MS trials. These include a treat-
ment duration that is often too short, discrepancies be-
tween the hypothesized mechanism of action and inclu-
sion criteria (inclusion of patients with little disease activ-
ity or very long disease duration in trials with substances
that have strong anti-inflammatory effect), premature con-
firmation of disease progression (already after 12 weeks),
or the lack of relevant PROM. The attempt to obtain sta-
tistical significance with high patient numbers despite of-
ten only minimal absolute differences in the relapse rate
between IMP and comparator drug are both of question-
able clinical relevance and of dubious cost-effectiveness
(insofar as these resources are then not available for other
trials).
Investigating outcomes that are particularly important
to patients has been the exception in drug approval trials
to date and where the case, they only serve as secondary
or explorative endpoints. These approaches are methodo-
logically inadequate to some extent, for example because
the PROM explorative endpoints were usually not sur-
veyed using validated measurement instruments (e.g.,
measurement of fatigue in the TRANSFORMS trial on
fingolimod with the unvalidated questionnaire “draft 39-
item version of the U-FIS”) [35].
Suggestions for improving phase III MS trial design
The hypothesized mechanism of action should be clearly
described at the beginning of the trial and should be
taken into consideration when designing the study. For
immunomodulatory drugs intended for treatment in
(highly) active disease stages (e.g., natalizumab,
ocrelizumab), this would mean that relapse rate could
continue to serve as endpoint. However, aspects such
as the severity of the relapse or the functional disability
and the remission should also be taken into account. To
establish the added benefit of a new drug, a clinically
significant effect on functionally debilitating relapses
(e.g., visual functioning, mobility, physical strength)
should be demonstrated. As the timing of relapses is
difficult to predict, the duration of observation in trials
that take relapse rate as endpoint should be at least 2
years.
For substances with a hypothesized effect on disability
progression, the observation period should be of suitable
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duration (at least 3 years, ideally up to 5 years). Currently,
disability progression is commonly established after only 12
or 24 weeks. However, recovery from relapse can take up to 6
or even 12 months, and temporary disability changes stem-
ming from previous relapses can lead to overestimation of
long-term disability progression. Consequently, disability pro-
gression should only be confirmed after 12 months, which
reduces confounding effect of incomplete recovery from re-
cent relapses [42].
The inclusion criteria for the trial subjects should take
into account the expected effect of the active substance and
be compatible with the primary endpoint. For example,
validation of a drug with hypothesized effect on disability
progression should include patients whose progression is
confirmed prior to inclusion in the trial. Otherwise, the
danger exists of including significant numbers of “stable”
patients or those with only slow progression. In such cases,
the drug being tested might indeed have an effect in the
subpopulation, but this might not be detected in the sample
due to the mild natural history of the cohort (false negative
result for the subpopulation in question). Conversely, a
“positive” effect could be the result of the actual subpopu-
lation of interest, but be mistakenly extended to include
patients with mild natural history (false positive result for
the subpopulation with mild natural history, see
ORATORIO trial, ocrelizumab).
For drugs with strong anti-inflammatory effect, focus
should be placed on including patients in early disease
phases with higher disease activity, instead of—as was
most recently the case in the CLARITY trial—a very
broad enrolment of the population, including patients
with low disease activity and extremely long disease
duration. By ensuring the inclusion criteria is compati-
ble with the hypothesized mode of action, it might be
possible to achieve clinically relevant results with small-
er case numbers, thereby sparing patients the risks in-
volved in testing new immunotherapies. The subjects
should also cover a wide age range (up to 60 or 65
years, as opposed to the currently usual age limit of
55) and age effects should be investigated, as a recent
meta-analysis demonstrated that age can affect the effi-
cacy of an immunomodulatory therapy [82]. Apart from
EDSS, it is imperative that a functional test of low-
contrast sensitivity (e.g., low contrast letter acuity using
Sloan charts) and mobility (e.g., 6-min walk test) be
performed to quantify disability, as vision and mobility
are the most important bodily symptoms from a patient
point of view [27].
The EMA guideline [30] recommends evaluating
health-related quality of life, although lack of data
precludes recommending any specific instruments.
Indeed, using established assessment instruments to quan-
tify health-related quality of life, as well as fatigue and
cognition, should become standard practice. Tools for
measuring quality of life include MSQOL 54 (Multiple
Sclerosis Qual i ty of Life-54) [38] , HAQUAMS
(Hamburg Quality of Life Questionnaire in Multiple
Sclerosis) [66], MSQLI (Multiple Sclerosis Quality of
Life Inventory) [39], or the recently developed Neuro-
QoL [51]. Fatigue and cognition can be measured using
the Fatigue Severity Scale (FSS) [37, 46] and BICAMS
(Brief International Cognitive Assessment for Multiple
Sclerosis) [32, 48], respectively. A simple further screen-
ing instrument for cognition is the SDMT (Symbol Digit
Modalities Test) [75]. The effect of limited vision and
mobility on quality of life should be quantified using the
established measurement instrument NEI-VFQ25
(National Eye Institute Visual Functioning Questionnaire
25) [40] or the MSWS-12 [23], as applies.
Cerebral or spinal MRI parameters can serve as second-
ary or explorative outcomes (e.g., T2 lesions, spinal cord
atrophy [2, 83]); however, the repeated application of
gadolinium-based MRI contrast agents should be avoided
due to safety concerns [14, 67]. Moreover, brain atrophy
measurements, although technically feasible in a clinical
study with rigorous standardization of assessments, are
not recommended as they are not yet transferable to gauge
prediction and monitoring of disease course in individual
patients, thus currently not supporting personalization of
medical services [3, 28, 61, 62, 81]. The same applies to
other advanced imaging modalities such as diffusion tensor
imaging, ultrahigh field MRI and others [47, 56, 59, 64,
69, 70, 72]. Most recently, the use of retinal optical coher-
ence tomography (OCT) for the quantification of axonal
and neuronal damage caused by MS is increasing [4, 10,
50, 52–54, 84]. This technique has been occasionally used
as outcome measure in clinical trials and might serve as
predictive diagnostics for disease course and response to
immunotherapy both in trial cohorts and individual sub-
jects in the future. A further suitable secondary or explor-
ative outcome that might be established in the near future
both for clinical studies and individualized prediction is the
identification of neurofilaments in serum as surrogate
marker of axonal damage in the CNS [1, 6, 7, 12, 43, 49,
73, 76].
Exclusively placebo-controlled trials with a duration of
more than 6 months that test disease-modifying drugs in
RRMS are ethically problematic. Moreover and important-
ly, the advantages and disadvantages of individual treat-
ment options cannot be identified by means of placebo-
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controlled studies. When selecting appropriate active com-
parators, care should be taken that the trial’s inclusion
criteria reflect both the study population and the active
comparator’s approval status. In trials with a PPMS popu-
lation, the lack of approved drugs (with the exception of
ocrelizumab) justifies the use placebo-controlled trials.
Ocrelizumab, which was recently approved, likely only
benefits a small subgroup of younger PPMS patients (up
to 45 years) with short disease duration (up to 15 years)
and disease activity in MRI (new T2 lesions, gadolinium-
enhancing lesions), and trialing against this substance in
other PPMS populations (older patients, longer disease du-
ration, no MRI activity) makes little sense and is moreover
not ethically acceptable.
Overall, the high demand of patients for studies in progres-
sive MS (SPMS, PPMS) continues. A significant number of
drugs, including some approved for treatment of RRMS, were
unsuccessfully tested in patients with progressive MS. The
reasons for this are manifold and include an incomplete un-
derstanding of the pathophysiology of progression, an insuf-
ficiently detailed grasp of themechanism of action of the drug,
and the shortcomings of the applied outcomes (such as the
EDSS with high inter-rater variability and disproportionate
weighting allocated to lower extremity functioning, or more
generally, the ability to walk).
The suggestions for improvement presented here
build to some extent on those recently published by
Ontaneda et al. ([55], see Text Box 5b). Importantly,
clinical researchers planning a trial should make use of
the EMA’s advice service, and ideally also involve the
European HTA (Health Technology Assessment) institu-
tions [29], of which the Federal Joint Committee (G-
BA) is the primary body in Germany [33]. The aim of
the consultation process should be ensuring that the trial
is designed to not only meet the requirements necessary
for market approval, but also to inform treatment deci-
sions and to perform an assessment of the added benefit
of the new drug compared to standard treatment. The
results of the consultation should be published to ensure
transparency.
P h a r m a c e u t i c a l c o m p a n i e s i n G e r m a n y
sometimes complain that the recommendations of drug
approval agencies and HTA institutions (IQWiG and G-
BA) diverge to some extent and that data from a single
phase III trial is interpreted differently by the EMA, on
the one hand, and the committees participating in the ear-
ly benefit assessment (IQWiG and G-BA), on the other.
However, this perspective does not take into account the
fact that the questions posed by the approval agencies
(“Does the new substance have a positive benefit-risk
balance?”) and the benefit assessment (“Does the new
substance have an added benefit compared to a ‘standard
therapy’?”) are very different. By necessity, this leads to
diverging demands on the trial design in the first instance,
and ultimately leads to different interpretation of the ob-
tained results in the final instance.
Despite our criticism of MS studies to date, we are aware
that planning a clinical trial and improving quality and patient
focus as discussed above also (have to) take into account a
wider health policy and regulatory framework, as well as fi-
nancial considerations. This complicates and could even hob-
ble design of a study that focuses exclusively on achieving
scientific insights into MS.
Expert recommendations
Fortunately, the therapeutic landscape for people with MS
has significantly broadened over the past 15 years. In par-
allel to the increasing number of available immunother-
apies, treatment strategies in MS have shifted from a mere
“relapse-prevention” approach to a personalized provision
of medical care as to the choice of the appropriate drugs and
their sequential application over the course of the disease.
This personalized provision should take patient preferences
as well as disease-related factors into consideration such as
objective clinical and radiographic findings but also very
burdensome symptoms such as fatigue, depression, and
cognitive impairment. This change in perspective on what
physicians want to accomplish for their patients has not
only been endorsed by clinicians and researchers but has
also been adopted by regulatory bodies such as EMA.
Therefore, future trial designs in MS should assign higher
relevance to these patient-reported outcomes and should
aim at implementing measures that can serve as predictive
markers for individual treatment response to new and in-
vestigational immunotherapies. This is an indispensable
prerequisite to maximize the benefit of individual patients
when participating in clinical trials and when starting on an
immunotherapy post approval. Moreover, such appropriate
trial designs and suitable enrolment criteria that correspond
to the mode of action of the study drug will facilitate
targeted prevention of adverse events, thus mitigating risks
for individual study participants. Finally, personalized pro-
vision of medical services prior to enrolment into clinical
trials must encompass utmost accuracy when diagnosing
MS and ruling out relevant differential diagnoses given that
newer and highly efficacious immunotherapies for MS
might cause harm in other MS mimics such as neuromyeli-
tis optica spectrum disorders and many others [5, 8, 9, 11,
15, 18, 19, 41, 44, 53, 68, 71].
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5a Text box “Suggestions for improving the design of
(R)RMS1/CIS trials”
5b Text box “Suggestions for improving the design of
PPMS/SPMS2 trials”
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